Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 380 | 399 | 439 | 451 | 494 | 610 | 1,044 | 759 |
| Operating profit | €m | 73 | 256 | ||||||
| Net profit | €m | 73 | 82 | 89 | 92 | 111 | 80 | 136 | 92 |
| EPS reported | € | 0.25 | 0.43 | ||||||
| Operating cashflow per share | € | 0.25 | 0.26 | ||||||
| Capex per share | € | 0.05 | 0.06 | ||||||
| FCF per share | € | 0.20 | 0.20 | ||||||
| Free cash flow | €m | 62 | 62 | ||||||
| Net debt | €m | 275 | 260 | ||||||
| Book value equity | €m | 745 | 774 | ||||||
| Book value per share | € | 2.38 | 2.47 | ||||||
| Number of shares | m | 313.07 | 313.39 | ||||||
| DPS (TTM paid) | € | 0.18 | 0.13 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 20.64 | 10.42 | ||||||
| P/B LTM | x | 2.16 | 1.82 | ||||||
| P/S LTM | x | 2.63 | 1.35 | ||||||
| P/FCF LTM | x | 25.74 | 22.84 | ||||||
| EV/EBITDA LTM | x | 18.65 | 10.02 | ||||||
| EV/Sales LTM | x | 3.11 | 1.60 | ||||||
| Earnings Yield LTM | % | 4.84% | 9.60% | ||||||
| FCF Yield | % | 3.88% | 4.38% | ||||||
| Quality | |||||||||
| ROE | % | 10.69% | 18.19% | ||||||
| ROIC | % | 5.71% | 18.01% | ||||||
| Operating margin | % | 11.92% | 24.55% | ||||||
| Gross margin | % | 37.42% | 29.90% | ||||||
| FCF/Sales | % | 10.22% | 5.90% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -30.56% | +4.88% | ||||||
| Sales Growth YoY | % | +23.66% | +58.37% | ||||||
| Net Income Growth YoY | % | -28.49% | +7.39% | ||||||
| FCF Growth | % | -17.86% | -21.55% | ||||||
| Operating Profit Growth | % | -32.05% | +8.85% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 3.47% | 2.83% | ||||||
| Dividend Growth | % | +32.63% | -28.49% | ||||||
| Payout Ratio | % | 71.18% | 41.18% | ||||||
| FCF/Debt | x | 0.15 | 0.16 | ||||||
| Net Debt/EBITDA | x | 2.87 | 1.64 | ||||||
| EBIT/Net interest | x | 11.51 | 23.22 | ||||||
| Net debt/market cap | % | 17.14% | 18.47% | ||||||
| Net debt/Equity | x | 0.37 | 0.34 | ||||||
| Gross debt/equity | x | 0.55 | 0.51 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free